Alpha1B adrenoceptor expression is a marker of reduced survival and increased tumor recurrence in patients with endometrioid ovarian cancer

Table 1 Distribution of adrenoceptor protein expression according to age, tumor type and tumor grade in patients with ovarian cancer

		Adrenergic receptor	Absent	Present	χ2	P
Age at diagnosis	< 49	α-1B	25 (66)	13 (34)	1.076	0.584
	50-69		55 (59)	38 (41)
	> 70		24 (54)	20 (46)
	< 49	α-2C	11 (29)	27 (71)	2.600	0.273
	50-69		38 (42)	52 (58)
	> 70		19 (45)	23 (55)
	< 49	β2	9 (31)	20 (69)	1.956	0.376
	50-69		36 (43)	47 (57)
	> 70		13 (33)	26 (67)
Tumour type	High grade serous	α-1B	49 (55)	40 (45)	14.648	0.005
	Low grade serous		4 (67)	2 (33)
	Endometrioid		25 (60)	17 (40)
	Clear cell		16 (94)	1 (6)
	Mucinous		4 (29)	10 (71)
	High grade serous	α-2C	44 (48)	47 (52)	11.038	0.026
	Low grade serous		4 (67)	2 (33)
	Endometrioid		8 (21)	31 (79)
	Clear cell		6 (35)	11 (65)
	Mucinous		5 (33)	10 (67)
	High grade serous	β2	25 (32)	54 (68)	13.559	0.009
	Low grade serous		1 (17)	5 (83)
	Endometrioid		20 (54)	17 (46)
	Clear cell		8 (61)	5 (39)
	Mucinous		1 (9)	10 (91)
Tumour grade	1	α-1B	11 (42)	15 (58)	3.472	0.176
	2		6 (55)	5 (45)
	3		81 (62)	50 (38)
	1	α-2C	9 (35)	17 (65)	0.456	0.796
	2		4 (36)	7 (64)
	3		54 (41)	77 (59)
	1	β2	4 (18)	18 (82)	4.236	0.12
	2		4 (44)	5 (56)
	3		47 (41)	68 (59)
Mortality (5 yr)	No	α-1B	55 (69)	25 (31)	4.821	0.028
	Yes		47 (52)	43 (48)
	< 5 yr	α-2C	31 (39)	48 (61)	0.001	0.969
	> 5 yr		34 (39)	52 (61)
	< 5 yr	β2	25 (36)	44 (64)	0.284	0.594
	> 5 yr		32 (41)	47 (59)

Proportion of patients showing each adrenoceptor (percentage).

Table 2 Distribution of adrenoceptor protein expression in patients with ovarian cancer according to clinical stage, chemotherapy received and chemotherapy failure

		Adrenergic receptor	Absent	Present	χ2	P
Clinical stage	1	α-1B	39 (65)	21 (35)	2.486	0.478
	2		12 (50)	12 (50)
	3		47 (59)	33 (41)
	4		4 (44)	5 (56)
	1	α-2C	17 (29)	41 (71)	6.014	0.111
	2		10 (42)	14 (58)
	3		38 (49)	40 (51)
	4		2 (25)	6 (75)
	1	β2	18 (37)	31 (63)	6.508	0.089
	2		4 (20)	16 (80)
	3		31 (42)	43 (58)
	4		5 (71)	2 (29)
Stage 1 vs other stages	Stage 1	α-1B	37 (63)	22 (37)	0.894	0.344
	Other stages		59 (55)	48 (45)
	Stage 1	α-2C	17 (29)	42 (71)	4.376	0.036
	Other stages		49 (45)	59 (55)
	Stage 1	β2	18 (36)	32 (64)	0.090	0.764
	Other stages		37 (39)	59 (61)
Chemotherapy regimen	Before surgery	α-1B	11 (58)	8 (42)	0.734	0.693
	After surgery		84 (57)	62 (43)
	Before surgery	α-2C	8 (42)	11 (58)	0.702	0.704
	After surgery		58 (40)	87 (60)
	Before surgery	β2	8 (47)	9 (53)	1.316	0.518
	After surgery		46 (36)	80 (64)
Chemotherapy resistance	Refractory	α-1B	8 (80)	2 (20)	2.647	0.266
	Resistant within 6 mo		4 (44)	5 (56)
	Responsive		72 (58)	52 (42)
	Refractory	α-2C	2 (25)	6 (75)	2.342	0.310
	Resistant within 6 mo		6 (60)	4 (40)
	Responsive		50 (41)	73 (59)
	Refractory	β2	5 (56)	4 (44)	1.010	0.604
	Resistant within 6 mo		4 (40)	6 (60)
	Responsive		40 (38)	64 (62)

Proportion of patients showing each adrenoceptor (percentage).

Table 3 A Cox regression analysis was performed to test the independence of tumor alpha1B protein expression as a biomarker compared to tumor grade, clinical stage and chemotherapy treatment

	HR	95%CI		P value
Cancer specific survival
Alpha1B expression	1.221	1.000	1.493	0.050
Tumor grade	1.353	0.992	1.844	0.056
Clinical stage	1.922	1.529	2.416	< 0.001
Chemotherapy	0.556	0.283	1.090	0.087
Tumor recurrence
Alpha1B expression	1.326	1.043	1.687	0.021
Tumor grade	1.390	0.949	2.035	0.091
Clinical stage	2.469	1.825	3.340	< 0.001
Chemotherapy	0.614	0.257	1.467	0.272

Tumor α1B protein is an independent marker of reduced cancer-associated survival and increased tumor recurrence.